651 related articles for article (PubMed ID: 17087305)
1. [Statins (HMG-CoA reductase inhibitors)].
Gotoda T
Nihon Rinsho; 2006 Nov; 64(11):2113-8. PubMed ID: 17087305
[TBL] [Abstract][Full Text] [Related]
2. [Lipid management--treatment goal and strategy].
Koshiyama H
Nihon Rinsho; 2006 Nov; 64(11):2102-6. PubMed ID: 17087303
[TBL] [Abstract][Full Text] [Related]
3. Optimal medical management of peripheral arterial disease.
Rice TW; Lumsden AB
Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
[TBL] [Abstract][Full Text] [Related]
4. [Hyperlipidemia in the elderly].
Kawano M
Nihon Rinsho; 2002 May; 60(5):1017-23. PubMed ID: 12029980
[TBL] [Abstract][Full Text] [Related]
5. [Guideline for management of lipid metabolism].
Ishibashi S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():675-8. PubMed ID: 12387068
[No Abstract] [Full Text] [Related]
6. [Treatment of lipid disorders for coronary heart disease prevention according to International Atherosclerosis Society recommendations].
Idzior-Waluś B
Przegl Lek; 1999; 56(5):372-6. PubMed ID: 10554575
[TBL] [Abstract][Full Text] [Related]
7. [Stroke prevention by statins].
Sawada N; Itoh H; Nakao K
Nihon Rinsho; 2002 May; 60(5):993-1001. PubMed ID: 12030004
[TBL] [Abstract][Full Text] [Related]
8. [Statins and diabetic hyperlipidemia].
Vergès B
Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):128-32. PubMed ID: 11240415
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein in 2005. Interview by Peter C. Block.
Ridker PM
J Am Coll Cardiol; 2005 Jul; 46(1):CS2-5. PubMed ID: 16007748
[TBL] [Abstract][Full Text] [Related]
10. Primary prevention trials: lessons learned about treating high-risk patients with dyslipidemia without known cardiovascular disease.
Ferdinand KC
Curr Med Res Opin; 2005 Jul; 21(7):1091-7. PubMed ID: 16004678
[TBL] [Abstract][Full Text] [Related]
11. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients.
Olyaei A; Greer E; Delos Santos R; Rueda J
Clin J Am Soc Nephrol; 2011 Mar; 6(3):664-78. PubMed ID: 21393488
[TBL] [Abstract][Full Text] [Related]
13. Do people with diabetes need statins?
White JR
Diabetes Educ; 2008; 34(4):664-73. PubMed ID: 18669808
[TBL] [Abstract][Full Text] [Related]
14. [Diabetes mellitus and hyperlipidemia].
Uchida N; Shuto Y; Oikawa S
Nihon Rinsho; 2001 Mar; 59 Suppl 3():733-7. PubMed ID: 11347163
[No Abstract] [Full Text] [Related]
15. [Clinical trials on protective efficacy of statins for cardiovascular events due to hyperlipidemia (J-LIT, 4S, CARE, LIPID etc)].
Higashikata T
Nihon Rinsho; 2004 Mar; 62 Suppl 3():628-36. PubMed ID: 15171447
[No Abstract] [Full Text] [Related]
16. Use of lipid-lowering agents (statins) during pregnancy.
Hosokawa A; Bar-Oz B; Ito S
Can Fam Physician; 2003 Jun; 49():747-9. PubMed ID: 12836860
[TBL] [Abstract][Full Text] [Related]
17. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
[TBL] [Abstract][Full Text] [Related]
18. Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
Svilaas A; Strandberg T; Eriksson M; Hildebrandt P; Westheim A
Scand Cardiovasc J; 2008 Aug; 42(4):279-87. PubMed ID: 18609053
[TBL] [Abstract][Full Text] [Related]
19. Coronary artery disease and diabetes.
Bohannon NJ
Postgrad Med; 1999 Feb; 105(2):66-8, 71-2, 77-80. PubMed ID: 10026704
[TBL] [Abstract][Full Text] [Related]
20. Lipid-lowering therapy and the patient with multiple risk factors: what have we learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)?
Sever PS
Am J Med; 2005 Dec; 118 Suppl 12A():3-9. PubMed ID: 16356801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
